Developer docs
API playgroundTry for free, no card

Search company profiles

Sword Bio

Full company profile

uuid000blb2

Namestring
Sword Bio
Legal namestring
Sword Diagnostics, Inc.
Websiteurl
swordbio.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Sword Bio (legal entity Sword Diagnostics, Inc., Delaware) is a GLP-compliant bioanalytical contract research organization providing assay development, validation, and sample analysis services to biotech and pharmaceutical companies developing biologic therapeutics, including monoclonal antibodies, fusion proteins, antibody-drug conjugates (ADCs), gene therapies, cell therapies, and biosimilars. Core offerings span Ligand Binding Assays (LBAs) including ELISA and Meso Scale Discovery (MSD) electrochemiluminescence platforms for pharmacokinetic (PK), immunogenicity (ADA and NAb), and biomarker quantification, complemented by cell-based assays, molecular assays (qPCR, dPCR), and flow cytometry. The proprietary Sword Swift™ reagent system delivers MSD-comparable detection sensitivity using standard fluorescent-plate-reader ELISA infrastructure. Services are executed under Non-GLP, GLP, and GCLP conditions and span discovery through clinical Phase IV, supporting IND, BLA, and MAA submissions.

The company operates through a direct sales-led GTM via VP-level business development executives covering the US East and West Coasts and senior scientific leadership engaging sponsors directly. Pricing is custom and project-based with no minimum project requirement, and project kickoff typically begins within 10-15 business days from signed scope. Sword Bio is privately held and founder-led by CEO David Dingott; scientific strategy is led by CSO Dr. Jim McNally (ex-BioAgilytix, CRISPR Therapeutics, Genzyme, Pfizer, EMD Serono, Shire). Operations are anchored by headquarters in Carmel, Indiana and the primary bioanalytical laboratory in Chicago, Illinois. Sponsors are biotech and pharma developers of biologics across preclinical and clinical stages, with modality emphasis on antibody therapeutics, gene and cell therapies, and bispecific or ADC programs.

Short descriptiontext

Sword Bio is a GLP-compliant bioanalytical contract research organization providing Ligand Binding Assay, pharmacokinetic, immunogenicity, and biomarker services for biotech and pharma developing biologics, using proprietary Sword Swift™ reagents with labs in Carmel, IN and Chicago, IL.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical services, contract research organization, pharmacokinetic assays, immunogenicity testing, biomarker assay development
Industry5 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioanalytical Contract Research Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Sword Bio operates as a contract research organization (CRO) providing bioanalytical services including assay development, validation, and sample analysis for biotech and pharmaceutical companies. Services are delivered on a project-by-project basis supporting preclinical and clinical studies under GLP, GCP, and RUO conditions. Revenue is generated through service fees for method development, validation, and sample testing projects of varying scope.

swordbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is determined on a project-by-project basis. No minimum project size required - the company supports projects of all sizes from single assay qualifications to large-scale clinical sample analysis programs.

swordbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sword Bio is a GLP-compliant bioanalytical contract research organization (CRO) that provides regulated laboratory services — assay development, validation, and sample analysis — to biotech and pharmaceutical sponsors developing biologic therapeutics, antibody therapeutics, cell therapies, and gene therapies. Services span pharmacokinetics, immunogenicity (ADA/NAb), biomarker quantification, cell-based assays, and molecular assays under GLP, GCLP, and RUO conditions. The company also offers the proprietary Sword Swift™ high-sensitivity ELISA detection reagent system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Projects typically initiate within 10-15 business days
+2 more records
Product overview1 text field

Sword Bio is a GLP-compliant bioanalytical contract research organization (CRO) offering a comprehensive portfolio of laboratory services for drug discovery and development. The company's offerings are organized as core service lines rather than a unified software platform. The portfolio includes Bioanalytics (Ligand Binding Assays), Pharmacokinetics (PK) Assays, Custom Biomarkers, Immunogenicity (ADA & NAb) testing, MSD Assays (singleplex and multiplex immunoassays), and the proprietary Sword Swift™ high-sensitivity ELISA reagent system. Complementary services include Cell-Based Services and Molecular Services for cell and gene therapy support. All services support preclinical and clinical stages under Non-GLP, GLP, and GCLP conditions, with expertise spanning antibody therapeutics, gene therapies, and small/large molecule biologics.

Product and service9 records
1Bioanalytics (Ligand Binding Assay Development)
CategoryBioanalytical Services
Description

Rapid development, optimization, qualification, and validation of Ligand Binding Assays (LBAs) tailored to client-specific needs for therapeutic proteins, serology, vaccines, nucleic acids, and immuno-oncology applications, run under Non-GLP or GLP conditions. The service supports immunogenicity assays, neutralizing antibody (NAb) assays, cell-binding assays, receptor binding phosphorylation assays, PK assays, PD assays, receptor occupancy assays, functional whole cell assays, and serology/vaccine development applications.

2Pharmacokinetics (PK) Assays
CategoryBioanalytical Services
Description

Development, qualification, and validation of sensitive quantitative assays to measure the pharmacokinetic activity of novel therapeutic drugs for preclinical and clinical studies under Non-GLP or GLP conditions.

3Custom Biomarkers
CategoryBioanalytical Services
Description

Development, qualification, validation, and sample analysis of sensitive, accurate, and precise quantitative assays to measure protein and non-protein biomarkers of drug efficacy, toxicity, and disease diagnosis, progression, or recurrence in preclinical or clinical samples.

4Immunogenicity (ADA & NAb Assays)
CategoryBioanalytical Services
Description

Development and validation of anti-drug antibody (ADA) and neutralizing antibody (NAb) methods including bridging assays, direct-binding assays, ACE, and SPEAD formats designed to meet client-specific project needs.

5MSD Assays (Meso Scale Discovery)
CategoryBioanalytical Services
Description

Complete suite of MSD singleplexed and multiplex immunoassays for biomarker quantitation supporting drug discovery, nonclinical, and clinical validation needs using S-PLEX, V-PLEX, U-PLEX, R-PLEX, and T-PLEX formats across all regulatory settings.

6Sword Swift™ (High-Sensitivity ELISA Detection Reagents)
CategoryProprietary Technology / Reagent Product
Description

Proprietary high-sensitivity ELISA detection reagents and signal amplification system, paired with a proprietary method development workflow, that provides sensitivity comparable to MSD assays for biomarker, protein, and therapeutic quantitation while being more cost-effective. Includes advanced signal amplification techniques that achieve lower detection limits and greater precision than standard ELISA systems, with assay development matching validated MSD sensitivity using standard fluorescent plate readers and HRP detection.

7Cell-Based Services
CategoryComplementary Bioanalytical Services
Description

Comprehensive suite of cell-based assay services including mechanism of action studies, CMC lot release and stability assessments, cellular immunogenicity assessments, and cytotoxicity evaluations using cell lines or primary cells.

8Molecular Services
CategoryComplementary Bioanalytical Services
Description

Molecular assays supporting cell and gene therapy development including qPCR, digital PCR (dPCR), CAR-T therapy support, AAV viral services, VCN testing, and gene expression analysis.

9Antibody Therapeutics Bioanalytical Support
CategoryModality-Specific Bioanalytical Services
Description

Specialized bioanalytical services for monoclonal antibodies, multidomain proteins, antibody-drug conjugates (ADCs), and biosimilars using ELISA and MSD platforms for PK, immunogenicity, and biomarker assessments.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioAgilytix is a specialized bioanalytical CRO offering PK, immunogenicity, biomarker, and cell-based services for biologics and gene therapies. It is the most direct competitor to Sword Bio, and two senior Sword Bio leaders (CSO Jim McNally, former CSO; VP BD West Coast Michael Losauro, former Senior Director of Strategic Accounts) joined from BioAgilytix.

TypeDirect peer
Description

Eurofins Bioanalytical Services provides small and large molecule PK, immunogenicity, and biomarker assay development across global lab sites. Direct competitor in the same LBA/MSD/immunogenicity service lines and a credible alternative for sponsors evaluating outsourced bioanalytical work.

TypeBroad incumbent
Description

Charles River is a large CRO offering bioanalytical, safety, and manufacturing services including the Skokie molecular biology unit that AM Rom (Sword Bio GM) previously led. It competes with Sword Bio on LBA, biomarker, and molecular services, but as part of a much broader portfolio.

TypeDirect peer
Description

Celerion is a clinical bioanalytical CRO offering PK/PD, immunogenicity, and biomarker services for early-stage clinical development. Directly comparable in size, modality focus, and target customer base.

TypeDirect peer
Description

Frontage provides bioanalytical, CMC, and preclinical services with strong LBA and biomarker capabilities serving biotech and pharma sponsors. Comparable in service mix and customer profile, with a larger U.S. and China footprint.

TypeBroad incumbent
Description

Q² Solutions is a clinical trials laboratory services joint venture (IQVIA/Quest) offering bioanalytical, central lab, and biomarker services. Competes with Sword Bio on bioanalytical work for clinical trials, but as part of a global full-service lab offering.

TypeBroad incumbent
Description

Labcorp Drug Development (spun off as Fortrea) operates a large central bioanalytical lab serving global clinical trials. Overlaps with Sword Bio in PK and immunogenicity support but at a fundamentally larger scale and broader scope.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO with bioanalytical capabilities supporting complex biologics and rare disease programs. Comparable in scale and emphasis on scientific engagement versus pure scale.

TypeBroad incumbent
Description

PPD, now part of Thermo Fisher's clinical research business, offers large-scale bioanalytical and central lab services for global clinical trials. Overlaps with Sword Bio on biomarker and immunogenicity work but operates at a much larger scale.

TypeDirect peer
Description

Cambridge Biomedical was a bioanalytical CRO specializing in PK, biomarker, and immunogenicity services, previously owned by Sword Bio's EVP of Sales and Marketing David Osband. The closest historical analog in scientific positioning even if its current ownership has changed.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sword Bio

Bioanalytical Contract Research Servicesswordbio.com

Sword Bio is a GLP-compliant bioanalytical contract research organization providing Ligand Binding Assay, pharmacokinetic, immunogenicity, and biomarker services for biotech and pharma developing biologics, using proprietary Sword Swift™ reagents with labs in Carmel, IN and Chicago, IL.

What Sword Bio does

Sword Bio (legal entity Sword Diagnostics, Inc., Delaware) is a GLP-compliant bioanalytical contract research organization providing assay development, validation, and sample analysis services to biotech and pharmaceutical companies developing biologic therapeutics, including monoclonal antibodies, fusion proteins, antibody-drug conjugates (ADCs), gene therapies, cell therapies, and biosimilars. Core offerings span Ligand Binding Assays (LBAs) including ELISA and Meso Scale Discovery (MSD) electrochemiluminescence platforms for pharmacokinetic (PK), immunogenicity (ADA and NAb), and biomarker quantification, complemented by cell-based assays, molecular assays (qPCR, dPCR), and flow cytometry. The proprietary Sword Swift™ reagent system delivers MSD-comparable detection sensitivity using standard fluorescent-plate-reader ELISA infrastructure. Services are executed under Non-GLP, GLP, and GCLP conditions and span discovery through clinical Phase IV, supporting IND, BLA, and MAA submissions.

The company operates through a direct sales-led GTM via VP-level business development executives covering the US East and West Coasts and senior scientific leadership engaging sponsors directly. Pricing is custom and project-based with no minimum project requirement, and project kickoff typically begins within 10-15 business days from signed scope. Sword Bio is privately held and founder-led by CEO David Dingott; scientific strategy is led by CSO Dr. Jim McNally (ex-BioAgilytix, CRISPR Therapeutics, Genzyme, Pfizer, EMD Serono, Shire). Operations are anchored by headquarters in Carmel, Indiana and the primary bioanalytical laboratory in Chicago, Illinois. Sponsors are biotech and pharma developers of biologics across preclinical and clinical stages, with modality emphasis on antibody therapeutics, gene and cell therapies, and bispecific or ADC programs.

Sword Bio firmographics

Firmographics
Name
Sword Bio
Legal name
Sword Diagnostics, Inc.
Website
https://swordbio.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Sword Bio is a GLP-compliant bioanalytical contract research organization providing Ligand Binding Assay, pharmacokinetic, immunogenicity, and biomarker services for biotech and pharma developing biologics, using proprietary Sword Swift™ reagents with labs in Carmel, IN and Chicago, IL.
Ownership category
akta.pro rank

Sword Bio industry classification

Industry
Product category
Bioanalytical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Bioanalytical services
  • Contract research organization
  • Pharmacokinetic assays
  • Immunogenicity testing
  • Biomarker assay development

Where Sword Bio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sword Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Contract Research Services: Sword Bio operates as a contract research organization (CRO) providing bioanalytical services including assay development, validation, and sample analysis for biotech and pharmaceutical companies. Services are delivered on a project-by-project basis supporting preclinical and clinical studies under GLP, GCP, and RUO conditions. Revenue is generated through service fees for method development, validation, and sample testing projects of varying scope.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Sword Bio product offering

Product offering

Core offering

Sword Bio is a GLP-compliant bioanalytical contract research organization (CRO) that provides regulated laboratory services — assay development, validation, and sample analysis — to biotech and pharmaceutical sponsors developing biologic therapeutics, antibody therapeutics, cell therapies, and gene therapies. Services span pharmacokinetics, immunogenicity (ADA/NAb), biomarker quantification, cell-based assays, and molecular assays under GLP, GCLP, and RUO conditions. The company also offers the proprietary Sword Swift™ high-sensitivity ELISA detection reagent system.

Product overview

Sword Bio is a GLP-compliant bioanalytical contract research organization (CRO) offering a comprehensive portfolio of laboratory services for drug discovery and development. The company's offerings are organized as core service lines rather than a unified software platform. The portfolio includes Bioanalytics (Ligand Binding Assays), Pharmacokinetics (PK) Assays, Custom Biomarkers, Immunogenicity (ADA & NAb) testing, MSD Assays (singleplex and multiplex immunoassays), and the proprietary Sword Swift™ high-sensitivity ELISA reagent system. Complementary services include Cell-Based Services and Molecular Services for cell and gene therapy support. All services support preclinical and clinical stages under Non-GLP, GLP, and GCLP conditions, with expertise spanning antibody therapeutics, gene therapies, and small/large molecule biologics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioanalytics (Ligand Binding Assay Development) Rapid development, optimization, qualification, and validation of Ligand Binding Assays (LBAs) tailored to client-specific needs for therapeutic proteins, serology, vaccines, nucleic acids, and immuno-oncology applications, run under Non-GLP or GLP conditions. The service supports immunogenicity assays, neutralizing antibody (NAb) assays, cell-binding assays, receptor binding phosphorylation assays, PK assays, PD assays, receptor occupancy assays, functional whole cell assays, and serology/vaccine development applications.
  • Pharmacokinetics (PK) Assays Development, qualification, and validation of sensitive quantitative assays to measure the pharmacokinetic activity of novel therapeutic drugs for preclinical and clinical studies under Non-GLP or GLP conditions.
  • Custom Biomarkers Development, qualification, validation, and sample analysis of sensitive, accurate, and precise quantitative assays to measure protein and non-protein biomarkers of drug efficacy, toxicity, and disease diagnosis, progression, or recurrence in preclinical or clinical samples.
  • Immunogenicity (ADA & NAb Assays) Development and validation of anti-drug antibody (ADA) and neutralizing antibody (NAb) methods including bridging assays, direct-binding assays, ACE, and SPEAD formats designed to meet client-specific project needs.
  • MSD Assays (Meso Scale Discovery) Complete suite of MSD singleplexed and multiplex immunoassays for biomarker quantitation supporting drug discovery, nonclinical, and clinical validation needs using S-PLEX, V-PLEX, U-PLEX, R-PLEX, and T-PLEX formats across all regulatory settings.
  • Sword Swift™ (High-Sensitivity ELISA Detection Reagents) Proprietary high-sensitivity ELISA detection reagents and signal amplification system, paired with a proprietary method development workflow, that provides sensitivity comparable to MSD assays for biomarker, protein, and therapeutic quantitation while being more cost-effective. Includes advanced signal amplification techniques that achieve lower detection limits and greater precision than standard ELISA systems, with assay development matching validated MSD sensitivity using standard fluorescent plate readers and HRP detection.
  • Cell-Based Services Comprehensive suite of cell-based assay services including mechanism of action studies, CMC lot release and stability assessments, cellular immunogenicity assessments, and cytotoxicity evaluations using cell lines or primary cells.
  • Molecular Services Molecular assays supporting cell and gene therapy development including qPCR, digital PCR (dPCR), CAR-T therapy support, AAV viral services, VCN testing, and gene expression analysis.
  • Antibody Therapeutics Bioanalytical Support Specialized bioanalytical services for monoclonal antibodies, multidomain proteins, antibody-drug conjugates (ADCs), and biosimilars using ELISA and MSD platforms for PK, immunogenicity, and biomarker assessments.

Quantifiable outcome

  • Projects typically initiate within 10-15 business days
  • +2 more outcomes

Companies that use Sword Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Sword Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Sword Bio partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Sword Bio competitors and assessment

Company assessment

Direct peers

  • BioAgilytix: BioAgilytix is a specialized bioanalytical CRO offering PK, immunogenicity, biomarker, and cell-based services for biologics and gene therapies. It is the most direct competitor to Sword Bio, and two senior Sword Bio leaders (CSO Jim McNally, former CSO; VP BD West Coast Michael Losauro, former Senior Director of Strategic Accounts) joined from BioAgilytix.
  • Eurofins Bioanalytical Services: Eurofins Bioanalytical Services provides small and large molecule PK, immunogenicity, and biomarker assay development across global lab sites. Direct competitor in the same LBA/MSD/immunogenicity service lines and a credible alternative for sponsors evaluating outsourced bioanalytical work.
  • Celerion: Celerion is a clinical bioanalytical CRO offering PK/PD, immunogenicity, and biomarker services for early-stage clinical development. Directly comparable in size, modality focus, and target customer base.
  • Frontage Laboratories: Frontage provides bioanalytical, CMC, and preclinical services with strong LBA and biomarker capabilities serving biotech and pharma sponsors. Comparable in service mix and customer profile, with a larger U.S. and China footprint.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with bioanalytical capabilities supporting complex biologics and rare disease programs. Comparable in scale and emphasis on scientific engagement versus pure scale.
  • Cambridge Biomedical (now part of a CRO platform): Cambridge Biomedical was a bioanalytical CRO specializing in PK, biomarker, and immunogenicity services, previously owned by Sword Bio's EVP of Sales and Marketing David Osband. The closest historical analog in scientific positioning even if its current ownership has changed.

Broad incumbents

  • Charles River Laboratories: Charles River is a large CRO offering bioanalytical, safety, and manufacturing services including the Skokie molecular biology unit that AM Rom (Sword Bio GM) previously led. It competes with Sword Bio on LBA, biomarker, and molecular services, but as part of a much broader portfolio.
  • Q² Solutions: Q² Solutions is a clinical trials laboratory services joint venture (IQVIA/Quest) offering bioanalytical, central lab, and biomarker services. Competes with Sword Bio on bioanalytical work for clinical trials, but as part of a global full-service lab offering.
  • Labcorp Drug Development (now Fortrea): Labcorp Drug Development (spun off as Fortrea) operates a large central bioanalytical lab serving global clinical trials. Overlaps with Sword Bio in PK and immunogenicity support but at a fundamentally larger scale and broader scope.
  • PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher's clinical research business, offers large-scale bioanalytical and central lab services for global clinical trials. Overlaps with Sword Bio on biomarker and immunogenicity work but operates at a much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sword Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sword Bio leadership team

Management profile

Number of profiles

Profiles10 records

Sword Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sword Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sword Bio

What does Sword Bio do?

Sword Bio is a GLP-compliant bioanalytical contract research organization (CRO) that provides regulated laboratory services — assay development, validation, and sample analysis — to biotech and pharmaceutical sponsors developing biologic therapeutics, antibody therapeutics, cell therapies, and gene therapies. Services span pharmacokinetics, immunogenicity (ADA/NAb), biomarker quantification, cell-based assays, and molecular assays under GLP, GCLP, and RUO conditions. The company also offers the proprietary Sword Swift™ high-sensitivity ELISA detection reagent system.

Is Sword Bio a public or private company?

Sword Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sword Bio founded?

Sword Bio was founded in -1. It employs 11 to 50 people.

Where is Sword Bio based?

Sword Bio is headquartered in Chicago, United States, in the North America region.

How does Sword Bio make money?

One revenue line is on record: contract Research Services.

Who are Sword Bio's main competitors?

Direct peers on record are BioAgilytix, Eurofins Bioanalytical Services, Celerion, Frontage Laboratories, Worldwide Clinical Trials and Cambridge Biomedical (now part of a CRO platform). Broad incumbents are Charles River Laboratories, Q² Solutions, Labcorp Drug Development (now Fortrea) and PPD (Thermo Fisher Scientific).

Does Sword Bio have an API?

No public API is recorded for Sword Bio.

What industry is Sword Bio in?

Sword Bio's product category is Bioanalytical Contract Research Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals